The Motley Fool's Top Stocks for Monster Returns in 2024

The Motley Fool's Stock Advisor team recommends buying Vertex Pharmaceuticals and e.l.f. Beauty, citing their strong pipelines and financial performance. Both companies have reported significant year-over-year increases in revenue and profits, with Vertex boasting a $10 billion cash reserve and e.l.f. Beauty seeing 80% growth in net sales.

author-image
Bijay Laxmi
New Update
The Motley Fool's Top Stocks for Monster Returns in 2024

The Motley Fool's Top Stocks for Monster Returns in 2024

The Motley Fool's Stock Advisor analyst team has identified 10 top growth, stocks, buy excluding Apple, that they believe have the potential to deliver monster returns for investors. This team has an impressive track record, having quadrupled the return of the S&P 500 since 2002.

Why this matters: The stock market's performance has a significant impact on the economy and individual investors' financial well-being. Identifying top-performing stocks can help investors make informed decisions and potentially achieve their long-term financial goals.

Two stocks that the team recommends buying now and holding for at least a decade are Vertex Pharmaceuticals (NASDAQ: VRTX) and e.l.f. Beauty (NYSE: ELF). Vertex is a leader in cystic fibrosis treatments, with a strong pipeline of medicines targeting rare and underserved diseases. In the first quarter of 2024, the company reported total profits of $1.1 billion on revenue of $2.7 billion, representing year-over-year increases of 57% and 13%, respectively. Vertex also has a hefty $10 billion in cash and investments on its balance sheet.

Vertex continues to benefit from high demand for its cystic fibrosis drugs, with a durable need for its medicines and a massive patient population. The company plans multiple new product launches before the end of the decade, each with unstoppable, growth, stocks, buy potential. Vertex is also developing a new gene editing therapy, Casgevy, with CRISPR Therapeutics, as well as a new triple combination cystic fibrosis therapy.

e.l.f. Beauty, on the other hand, has evolved significantly over the years, focusing on affordable, high-quality cosmetics and skincare products. The company boasts a strong online presence and lucrative partnerships with big-name retailers like Target, Walmart, and Ulta Beauty. In the first nine months of fiscal 2024, e.l.f. Beauty generated net sales of $703 million, up 80% from the same period the prior year. The company has a relatively asset-light business model, with a robust online and brick-and-mortar retail network and an increasingly impressive balance sheet.

The Motley Fool's Stock Advisor service provides investors with a blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. Investors with cash to spare may want to start or add to a position in Vertex Pharmaceuticals and e.l.f. Beauty, considering their strong pipelines, financial performance, and growth potential.

Key Takeaways

  • Motley Fool's Stock Advisor team recommends 10 growth stocks, excluding Apple, for monster returns.
  • Vertex Pharmaceuticals (VRTX) and e.l.f. Beauty (ELF) are two top picks for long-term growth.
  • Vertex Pharmaceuticals leads in cystic fibrosis treatments with a strong pipeline and $10B in cash.
  • e.l.f. Beauty offers affordable cosmetics and skincare with a strong online presence and retail partnerships.
  • Motley Fool's Stock Advisor service provides guidance and regular updates for building a successful portfolio.